CIBRN 2019 Q5: Biosimilars have been available in Canada for several years and yet are not being prescribed or used to same degree as they are in other countries. Inflectra and Remsima are used at a rate of 5-10% in Canada after being available for four years, while countries like Norway and the United Kingdom have respective use rates of 98% and 90%. What factors can explain these discrepancies? Should Canada be doing more to increase the use of biosimilars?

To view this question, please login.